CSCI שיעור רווח גולמי Aeterna Zentaris

סמלים רשמיים של חברת Aeterna Zentaris (CSCI)

COSCIENS Biopharma Inc. (CSCI) generates revenue through Macrilen licenses and the sale of diagnostic tests. The company's strategy relies on high-margin therapies for rare endocrine pathologies and growth hormone deficiency. The business is currently focusing on the organic development of its pipeline following the integration of new assets. The gross profit margin as a percentage of revenue illustrates production efficiency, while the 45.50 level reflects the status of the profitability parameter.

COSCIENS Biopharma Inc. (CSCI): שולי רווח גולמי מ-10.08.2024 עד 14.09.2025

פילוחים אנליטיים ודוחות נתונים של חברת COSCIENS Biopharma Inc (CSCI)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח בסיסי של החברה:CSCI - COSCIENS Biopharma
מוצר עיקרי של COSCIENS Biopharma

For a fundamental valuation of COSCIENS Biopharma Inc. (CSCI), understanding the monetization efficiency of its intellectual property is critical. Gross margin measures the profit share after deducting direct production costs, reflecting the company's ability to convert revenue into operating capital. The annual gross margin trend demonstrates the scalability potential of the biopharmaceutical business, where proprietary molecules allow for the minimization of cost of goods sold amid global sales growth.